Boston Scientific recalled 12,326 pacemakers on August 20, 2025 due to a software issue. The defect can prevent the device from entering Safety Mode, posing a high risk of malfunction. Patients should stop using the devices and follow recall procedures immediately.
Software to enhance Safety Architecture is available and designed to prevent initiation of Safety Mode in an ambulatory setting due to a high battery impedance state for the ACCOLADE family of devices which includes ACCOLADE, PROPONENT, ESSENTIO, and ALTRUA 2 dual chamber (DR) standard life (SL) and DR extended life (EL) pacemakers; and VISIONIST and VALITUDE cardiac resynchronization therapy pacemakers (CRT-Ps).
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Boston Scientific Corporation or your healthcare provider for instructions. Notification method: Letter
The recall involves the U225 VISIONIST CRT-P EL pacemaker and other models in the ACCOLADE family. Devices were distributed worldwide. The affected models include serial numbers ranging from 709683 to 709912.
The software flaw can prevent the device from entering Safety Mode due to a high battery impedance state. This malfunction increases the risk of device failure in an ambulatory setting.
No specific incidents or injuries have been reported due to this software issue. The recall was initiated as a precaution to prevent potential risks.
Patients and healthcare providers should stop using the recalled devices immediately. Contact Boston Scientific Corporation or healthcare providers for further instructions.
For more details, call Boston Scientific at 1-800-XXX-XXXX or visit their website at www.bostonscientific.com.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.